Assays
The BD SurePath™ collection vial is designed to improve patient care while providing physicians with the convenience of a single-source collection for Pap screening and molecular diagnostic testing
The BD SurePath™ Liquid-based Pap Test and the BD Onclarity™ HPV Assay provide HPV primary screening, co-testing and cytology primary with ASCUS reflex
When used with the BD Totalys™ MultiProcessor, the BD SurePath™ collection vial 2D barcodes allow Positive Sample Identification from collection through cytological and molecular testing, providing confidence in the results
The BD SurePath™ Liquid-based Pap Test can be processed according to the throughput and the automation levels needed. BD Totalys™ MultiProcessor or BD PrepMate™ (sample preparation, including cell enrichment), BD Totalys™ SlidePrep (slide preparation and staining) and BD FocalPoint™ GS Imaging System (slide analysis)
With BD SurePath™ Liquid-based Pap Test, the head of the collection device is deposited directly into the BD SurePath™ collection vial, so 100% of the sample is sent to the laboratory – unlike the rinse-and-swirl technique, which can result in an average of 37% of the cells being discarded5
The unique BD cell enrichment process separates and removes blood, mucus and interfering materials from the sample, meaning the most diagnostically relevant material is transferred to the slide6
Up-front accuracy leads to fewer patient callbacks, which could reduce patient anxiety and eliminate any risk of loss to follow-up, whilst removing the delay in receiving an actionable result
Fewer unsatisfactory results reduce the need for reprocessing samples and rescheduling patients, thus lessening the burden on the lab and nursing staff
The BD SurePath™ ethanol-based preservative is safe for health care professionals and lab personnel & safe for transport and storage
* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916. 2. Fontaine D et al. BMJ Open. 2012;2(2):e000847. 3. Fremont-Smith M et al. Cancer. 2004;
102(5):269–279. 4. Rozemeijer K et al. BMJ. 2017;356:j504. 5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174. 6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153.
